Abstract
Progress in the assessment of immunogenicity over the past decade has been rapid; therapeutics in late-phase clinical studies today are subject to antidrug antibody analyses that have evolved considerably since the start of their clinical development. Data from bridging and direct ELISA methods used for the analysis of antidrug antibodies generated in response to an antibody therapeutic will be presented. The case study will highlight some of the challenges faced and the learning points gained from supporting immunogenicity analysis for these therapeutics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
